Skip to main content
    A

    Anixa Biosciences Inc (ANIX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.55
    -0.07 (-2.67%)

    Market Cap: $91.08M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anixa Biosciences Inc (ANIX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Anixa Biosciences are XBiotech (XBIT), Immunic (IMUX) and Codexis (CDXS). By market cap, Anixa Biosciences ranks 6th of the 13 companies on this page; Atrium Therapeutics, Inc. Common Stock (RNA) is the largest at $162.00M.

    Peer Comparison

    ANIX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Anixa Biosciences (ANIX)$91.08MN/AN/A0.0%N/A0.0%0.00%
    XBiotech Inc (XBIT)$59.76MN/AN/A0.0%N/A-93.3%0.00%
    Immunic Inc (IMUX)$102.61MN/AN/A0.0%N/A0.0%0.00%
    Codexis Inc (CDXS)$127.13MN/AN/A-21.8%N/A124.0%0.00%
    Atrium Therapeutics, Inc. Common Stock (RNA)$162.00MN/A3.3x-180.9%-44.5%24.2%0.00%
    Coherus BioSciences Inc (CHRS)$81.21MN/A1.5x-253.4%-144.8%23.4%0.00%
    Champions Oncology Inc (CSBR)$65.49MN/A1.0x-1.9%N/A8.8%0.00%
    MAIA Biotechnology Inc. (MAIA)$61.75MN/AN/A0.0%N/A0.0%0.00%
    Tenax Therapeutics Inc (TENX)$73.77MN/AN/A0.0%N/A0.0%0.00%
    Nkarta Inc (NKTX)$85.23MN/AN/A0.0%N/A0.0%0.00%
    MacroGenics Inc (MGNX)$140.60MN/A1.2x-36.6%-108.7%-64.8%0.00%
    Innate Pharma (IPHA)$154.15MN/A17.6x0.0%489.8%16.5%0.00%
    ImageneBio, Inc. (IMA)$43.22MN/A68.5x0.0%N/A0.0%0.00%
    Peer median$83.22MN/A2.4x0.0%-76.6%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Anixa Biosciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    XBiotech Inc (XBIT)
    XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases.
    XBIT competitors
    Immunic Inc (IMUX)
    Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune...
    IMUX competitors
    Codexis Inc (CDXS)
    Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
    CDXS competitors
    Atrium Therapeutics, Inc. Common Stock (RNA)
    Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies.
    RNA competitors
    Coherus BioSciences Inc (CHRS)
    Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States.
    CHRS competitors
    Champions Oncology Inc (CSBR)
    Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States.
    CSBR competitors
    MAIA Biotechnology Inc. (MAIA)
    MAIA Biotechnology Inc. is an innovative biotechnology company focused on developing cutting-edge cancer therapies that significantly improve patient outcomes...
    MAIA competitors
    Tenax Therapeutics Inc (TENX)
    Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing...
    TENX competitors
    Nkarta Inc (NKTX)
    Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer.
    NKTX competitors
    MacroGenics Inc (MGNX)
    MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States.
    MGNX competitors
    Innate Pharma (IPHA)
    Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France...
    ImageneBio, Inc. (IMA)
    ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases.
    IMA competitors

    Frequently Asked Questions About ANIX

    Who are Anixa Biosciences' main competitors?

    The companies most similar to Anixa Biosciences include XBiotech (XBIT), Immunic (IMUX), Codexis (CDXS), Atrium Therapeutics, Inc. Common Stock (RNA) and Coherus BioSciences (CHRS), listed from the closest match.

    Who is Anixa Biosciences' biggest competitor?

    Atrium Therapeutics, Inc. Common Stock (RNA) is the largest of the similar companies at $162.00M; XBiotech (XBIT) is the closest match by business profile, size, sector and industry.

    How does ANIX stock compare with its competitors?

    ANIX's net margin is 0.0% against a peer median of 0.0%.

    Which of Anixa Biosciences' competitors pays a higher dividend?

    Anixa Biosciences pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Anixa Biosciences bigger than its competitors?

    No. Anixa Biosciences is 6th by market cap among the 13 companies on this page; the largest is Atrium Therapeutics, Inc. Common Stock (RNA) at $162.00M.